Tests a low-dose combination pill for essential hypertension in adults
Tests a low-dose pill of candesartan, amlodipine and indapamide in adults with essential hypertension.
Key facts
- Who runs it
- Shin Poong Pharmaceutical Co. Ltd.
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 252 people, planned
- Started
- 5 Dec 2024
- Planned end
- 28 Feb 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SPC1001 Low
- SPC5002
- SPC5003
- SPC5004
- Record updated
- 14 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with essential hypertension (high blood pressure with no other known cause). It tests a three-drug combination pill against two-drug treatments for 8 weeks.
- Age
- 19 to 75 years
- Sex
- Men and women
- Disease stage
- Essential hypertension. Blood pressure at the screening visit must meet set levels, which the record does not list.
Main reasons for not taking part
- Blood pressure at screening and randomization of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg
- Other conditions, which the record does not list
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria
Who cannot take part
- Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 75 years old?
Where in South Korea
- CHA Gangnam Medical Center, CHA UniversitySeoul, South KoreaEnrolling by invitation
About the trial
What the trial wants to find out
- Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to dual-component therapies of each ingredient for 8 weeks. Additionally, it seeks to confirm the contribution of each component at low doses.
Read full original descriptionShow less
- Inclusion Criteria: Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.
- Exclusion Criteria: Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.
- Methods: This study is a multicenter, randomized, double-blind, parallel-group, phase 2b clinical trial to evaluate the safety and efficacy of the investigational drug after 8 weeks of administration.
Screening assessments will be conducted within 4 weeks prior to randomization, and patients who meet the inclusion and exclusion criteria at the screening visit will be enrolled in the study after providing informed consent. These participants will undergo a 2-week run-in period during which they will take a placebo and participate in a lifestyle modification program.
The 4 groups in the trial
- SPC1001 LowExisting treatment, for comparison
low-dose combination therapy
- SPC5002Existing treatment, for comparison
low-dose combination therapy
Treatment: SPC1001 Low and SPC5002
- SPC5003Existing treatment, for comparison
low-dose combination therapy
Treatment: SPC1001 Low and SPC5003
- SPC5004Existing treatment, for comparison
low-dose combination therapy
Treatment: SPC1001 Low and SPC5004
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Randomized, Double-blind, Parallel, Phase 2b Study to Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
- Plain-language title
- Tests a low-dose combination pill for essential hypertension in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07064525, who can take part
- Record updated
- 14 July 2025